rigo nodularis and atopic dermatitis – and the latest from our Dermatological Skincare and Injectable Aesthetics portfolios. This demonstrates how Galderma continues to move from strength to strength, as a category leader in dermatology with a strong portfolio spanning the full spectrum of this fast-growing market.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

New data on atopic dermatitis and prurigo nodularis

New data on Nemluvio reinforce its benefit for a broad range of patients with prurigo nodularis and atopic dermatitis.

An oral presentation will report new data on the efficacy of Nemluvio treatment up to Week 16 across different pruriginous lesion types in patients with prurigo nodularis from the phase III OLYMPIA program. This will be presented on Friday, March 7.

The company will also share data demonstrating the continuous response with Nemluvio up to 56 weeks in patients with moderate-to-severe ato
=*=*=*=*=*=
当前为第3/13页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页